Cdai Score Calculator

Calculate Clinical Disease Activity Index for rheumatoid arthritis monitoring. Enter values for instant results with step-by-step formulas.

Share this calculator

X Facebook LinkedIn

Formula

CDAI = TJC28 + SJC28 + PGA + EGA

CDAI is the simple arithmetic sum of four components: TJC28 = tender joint count (0-28 joints), SJC28 = swollen joint count (0-28 joints), PGA = patient global assessment (0-10 cm VAS), EGA = evaluator/physician global assessment (0-10 cm VAS). Score range: 0-76. Remission <= 2.8, Low 2.8-10, Moderate 10-22, High > 22.

Worked Examples

Example 1: Active RA Needing Treatment Escalation

Problem: A patient on methotrexate has 8 tender joints, 6 swollen joints. Patient rates disease activity at 7/10 and physician rates it at 6/10.

Solution: CDAI = Tender Joints + Swollen Joints + Patient Global + Physician Global\nCDAI = 8 + 6 + 7 + 6\nCDAI = 27

Result: CDAI: 27 | High Disease Activity (> 22) | Escalate therapy - consider biologic DMARD

Example 2: Good Response After Biologic Therapy

Problem: After 6 months on adalimumab, a patient has 1 tender joint, 0 swollen joints, patient global 1/10, physician global 1/10.

Solution: CDAI = 1 + 0 + 1 + 1\nCDAI = 3.0\nPrevious CDAI was 27, improvement = 24 points (major improvement)

Result: CDAI: 3.0 | Low Disease Activity (2.8-10) | Near remission, continue current therapy

Frequently Asked Questions

What is the CDAI and how does it differ from DAS28?

The Clinical Disease Activity Index (CDAI) is a composite measure for assessing rheumatoid arthritis disease activity developed by Dr. Daniel Aletaha and colleagues. Unlike the DAS28, the CDAI is a simple arithmetic sum of four components: tender joint count (0-28), swollen joint count (0-28), patient global assessment (0-10 cm VAS), and physician global assessment (0-10 cm VAS). The key advantage over DAS28 is that CDAI does not require any laboratory tests, making it immediately calculable at the bedside during the clinical encounter without waiting for blood work. This makes it particularly practical for point-of-care treatment decisions in busy rheumatology clinics.

What are the CDAI thresholds for disease activity levels?

The CDAI uses validated cutoff values to classify rheumatoid arthritis disease activity into four categories. Remission is defined as a CDAI score of 2.8 or less, which is a stringent criterion that requires very few affected joints and minimal global assessments. Low disease activity is defined as a score between 2.8 and 10, representing an acceptable alternative treatment target. Moderate disease activity encompasses scores from 10 to 22, indicating the need for treatment adjustment. High disease activity is defined as a score above 22, signaling that aggressive treatment escalation is warranted. These thresholds were derived from comparison with clinician decisions and have been validated in multiple international cohorts.

Why does the CDAI not include laboratory values?

The CDAI was deliberately designed without laboratory components to address several practical limitations of laboratory-dependent scores like the DAS28. Blood test results are frequently not available at the time of the clinical visit, forcing treatment decisions to be deferred or made without formal disease activity scoring. ESR and CRP can be influenced by non-RA factors including infections, obesity, age, and other inflammatory conditions, potentially confounding the disease activity assessment. By eliminating laboratory requirements, the CDAI enables immediate, point-of-care scoring during every visit. Validation studies have shown that the CDAI performs comparably to DAS28 and SDAI for classifying disease activity and tracking treatment response.

How is the physician global assessment performed for CDAI?

The physician global assessment (also called evaluator global assessment or EGA) is the treating physician or healthcare provider assessment of overall disease activity on a visual analog scale from 0 to 10 centimeters, where 0 represents no disease activity and 10 represents maximum disease activity. The physician considers all available information at the time of assessment, including the joint examination findings, patient-reported symptoms, laboratory results if available, and clinical impression. This component is unique to the CDAI and SDAI and is not part of the DAS28. Inter-rater variability is a known limitation, as different physicians may assign different scores to the same patient. Training and calibration among assessors can help improve consistency.

How does CDAI fit into treat-to-target strategies?

The CDAI is endorsed by the American College of Rheumatology (ACR) and EULAR as one of the acceptable composite measures for implementing treat-to-target (T2T) strategies in rheumatoid arthritis. In the T2T approach, a specific disease activity target (ideally remission, or alternatively low disease activity) is selected, and treatment is systematically adjusted at regular intervals until the target is achieved. The CDAI is particularly well-suited for T2T because it can be calculated immediately during each visit without laboratory delays, enabling real-time treatment decisions. The recommended monitoring interval is every 1 to 3 months during active disease adjustment, extending to every 3 to 6 months once the target is reached.

Is CDAI remission more stringent than DAS28 remission?

Yes, CDAI remission (score of 2.8 or less) is generally more stringent than DAS28-ESR remission (score below 2.6). Studies comparing the two definitions have shown that patients meeting DAS28 remission criteria often still have residual swollen joints and may not meet CDAI remission criteria. This discrepancy occurs because the DAS28 formula uses logarithmic and square root transformations that can mathematically produce remission scores even when several joints remain affected, particularly if the ESR is low and the patient global assessment is favorable. The Boolean ACR/EULAR remission criteria are even more stringent, requiring tender joint count of 1 or less, swollen joint count of 1 or less, CRP of 1 mg/dL or less, and patient global of 1 or less.